Small molecule inhibitors of Candida albicans biofilm formation

白色念珠菌生物膜形成的小分子抑制剂

基本信息

  • 批准号:
    7455135
  • 负责人:
  • 金额:
    $ 16.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Candidiasis represents now the fourth most frequent nosocomial infection in the US and worldwide and C. albicans remains the most frequent causative agent of candidiasis. Unfortunately these infections are associated with unacceptably high morbidity and mortality rates. A variety of manifestations of candidiasis are associated with biofilm formation on the surface of different types of surfaces. Biofilm formation carries important consequences since sessile cells in biofilms display phenotypic traits that are dramatically different from their planktonic counterparts, such as increased resistance to antifungal agents and protection from host defenses. Once established, biofilms have the potential to initiate or prolong infections by providing a safe reservoir from which organisms can invade local tissue, seed new infection sites, or resist eradication efforts. The net effect is that Candida biofilms adversely impact the health of these patients, with increasing frequency and severity, and with soaring economic sequelae. Therefore, the main objective of the proposed studies is to devise novel strategies to prevent C. albicans biofilm formation. To this end we will: i) use a phenotype-based approach based on the high throughput screening for small molecule compounds which inhibit C. albicans biofilm formation, and ii) characterize the biofilm-inhibitory effects of selected bioactive molecules identified as "hits" and "leads" during the initial screens. These assays take advantage of a simple, rapid, robust, accurate and highly reproducible microtiter-based model for the formation of Candida biofilms developed in this laboratory that is ideally suited for automation and high throughput applications. Small-molecule-based approaches provide powerful means to address experimentally challenging and complex biological phenomena, such as biofilm formation, while simultaneously identifying new potential targets for drug development. to public health: Biofilm formation has severe consequences for human health. The main idea behind this study is that by eliminating the ability of C. albicans to form biofilms, a substantial reduction in morbidity, mortality and extended hospital stay can be achieved while simultaneously reducing healthcare costs.
描述(由申请人提供):念珠菌病现在是美国和全世界第四大最常见的医院感染,白色念珠菌仍然是念珠菌病最常见的病原体。不幸的是,这些感染伴随着令人无法接受的高发病率和死亡率。念珠菌病的多种表现与不同类型表面的生物膜形成有关。生物膜的形成具有重要的意义,因为生物膜中的无根细胞表现出与浮游细胞截然不同的表型特征,例如对抗真菌剂的抵抗力增强和对宿主防御的保护。一旦建立,生物膜有可能通过提供一个安全的储存库来启动或延长感染,生物体可以从该储存库侵入局部组织,播种新的感染位点,或抵抗根除努力。最终的结果是,念珠菌生物膜对这些患者的健康产生了不利的影响,其频率和严重程度都在增加,经济后遗症也在飙升。因此,提出的研究的主要目的是设计新的策略来防止白色念珠菌生物膜的形成。为此,我们将:i)使用基于表型的方法,基于高通量筛选抑制白色念珠菌生物膜形成的小分子化合物,ii)表征在初始筛选中被确定为“命中”和“先导”的选定生物活性分子的生物膜抑制作用。这些检测利用了一个简单、快速、稳健、准确和高度可重复的基于微滴的假丝酵母生物膜形成模型,该模型是本实验室开发的,非常适合自动化和高通量应用。基于小分子的方法提供了强大的手段来解决实验上具有挑战性和复杂的生物现象,如生物膜的形成,同时确定药物开发的新潜在靶点。对公众健康:生物膜的形成对人体健康有严重后果。这项研究背后的主要思想是,通过消除白色念珠菌形成生物膜的能力,可以大幅降低发病率、死亡率和延长住院时间,同时降低医疗成本。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms.
  • DOI:
    10.1111/j.1439-0507.2011.02047.x
  • 发表时间:
    2012-01
  • 期刊:
  • 影响因子:
    4.9
  • 作者:
    Martins M;Henriques M;Lopez-Ribot JL;Oliveira R
  • 通讯作者:
    Oliveira R
A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms.
  • DOI:
    10.3791/2287
  • 发表时间:
    2010-10-21
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Pierce, Christopher G;Uppuluri, Priya;Lopez-Ribot, Jose L
  • 通讯作者:
    Lopez-Ribot, Jose L
Candida albicans biofilm chip (CaBChip) for high-throughput antifungal drug screening.
用于高通量抗真菌药物筛选的白色念珠菌生物膜芯片(CaBChip)。
  • DOI:
    10.3791/3845
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Srinivasan,Anand;Lopez-Ribot,JoseL;Ramasubramanian,AnandK
  • 通讯作者:
    Ramasubramanian,AnandK
Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms.
  • DOI:
    10.1007/s11046-009-9264-y
  • 发表时间:
    2010-05
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Martins, Margarida;Uppuluri, Priya;Thomas, Derek P.;Cleary, Ian A.;Henriques, Mariana;Lopez-Ribot, Jose L.;Oliveira, Rosario
  • 通讯作者:
    Oliveira, Rosario
An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow.
  • DOI:
    10.4161/viru.1.6.13186
  • 发表时间:
    2010-11
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Priya Uppuluri;J. Lopez-Ribot
  • 通讯作者:
    Priya Uppuluri;J. Lopez-Ribot
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jose L. Lopez-Ribot其他文献

Protocol optimization for a fast, simple and economical chemical reduction synthesis of antimicrobial silver nanoparticles in non-specialized facilities
  • DOI:
    10.1186/s13104-019-4813-z
  • 发表时间:
    2019-11-27
  • 期刊:
  • 影响因子:
    1.700
  • 作者:
    Roberto Vazquez-Muñoz;M. Josefina Arellano-Jimenez;Fernando D. Lopez;Jose L. Lopez-Ribot
  • 通讯作者:
    Jose L. Lopez-Ribot
Fungal biofilms in human health and disease
人类健康与疾病中的真菌生物膜
  • DOI:
    10.1038/s41579-025-01147-0
  • 发表时间:
    2025-02-05
  • 期刊:
  • 影响因子:
    103.300
  • 作者:
    Gordon Ramage;Ryan Kean;Riina Rautemaa-Richardson;Craig Williams;Jose L. Lopez-Ribot
  • 通讯作者:
    Jose L. Lopez-Ribot
Antifungal therapy of emCandida/em biofilms: Past, present and future
念珠菌生物膜的抗真菌治疗:过去、现在和未来
  • DOI:
    10.1016/j.bioflm.2023.100126
  • 发表时间:
    2023-12-01
  • 期刊:
  • 影响因子:
    4.900
  • 作者:
    Olabayo H. Ajetunmobi;Hamid Badali;Jesus A. Romo;Gordon Ramage;Jose L. Lopez-Ribot
  • 通讯作者:
    Jose L. Lopez-Ribot

Jose L. Lopez-Ribot的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jose L. Lopez-Ribot', 18)}}的其他基金

BSL3 Drug Screening Core
BSL3 药物筛选核心
  • 批准号:
    10363478
  • 财政年份:
    2022
  • 资助金额:
    $ 16.97万
  • 项目类别:
BSL3 Drug Screening Core
BSL3 药物筛选核心
  • 批准号:
    10541228
  • 财政年份:
    2022
  • 资助金额:
    $ 16.97万
  • 项目类别:
High Throughput Screening of Medicines for Malaria Ventures Chemical Libraries to Identify Novel Inhibitors of Candida auris
疟疾药物的高通量筛选帮助化学库鉴定新型耳念珠菌抑制剂
  • 批准号:
    10383652
  • 财政年份:
    2021
  • 资助金额:
    $ 16.97万
  • 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
  • 批准号:
    10320258
  • 财政年份:
    2019
  • 资助金额:
    $ 16.97万
  • 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
  • 批准号:
    10335279
  • 财政年份:
    2019
  • 资助金额:
    $ 16.97万
  • 项目类别:
Screening a Target-Based Repurposing Library for Activity against Fungal Pathogens and Subsequent Preclinical Development of Leading Candidates
筛选基于靶点的再利用文库的抗真菌病原体活性以及主要候选药物的后续临床前开发
  • 批准号:
    10544529
  • 财政年份:
    2019
  • 资助金额:
    $ 16.97万
  • 项目类别:
Development of novel chemical series of Candida albicans biofilm inhibitors
白色念珠菌生物膜抑制剂新型化学系列的开发
  • 批准号:
    8951343
  • 财政年份:
    2015
  • 资助金额:
    $ 16.97万
  • 项目类别:
Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis
抗新生儿念珠菌病单克隆抗体 (Mab) 生物制剂的开发
  • 批准号:
    8425740
  • 财政年份:
    2013
  • 资助金额:
    $ 16.97万
  • 项目类别:
Development of Monoclonal Antibody (Mab) Biologics against Neonatal Candidiasis
抗新生儿念珠菌病单克隆抗体 (Mab) 生物制剂的开发
  • 批准号:
    8719015
  • 财政年份:
    2013
  • 资助金额:
    $ 16.97万
  • 项目类别:
Targeting virulence against oral candidiasis in HIV/AIDS
针对艾滋病毒/艾滋病口腔念珠菌病的毒力
  • 批准号:
    9234520
  • 财政年份:
    2013
  • 资助金额:
    $ 16.97万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了